Cliff Asness’s Forte Biosciences FBRX Stock Holding History

Cliff Asness’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-30	Closed	-$74K	–	2123
2019 Q2	$74K	Sell	30 -5	-14%	-$14.8K	﹤0.01%	2047
2019 Q1	$143K	Buy	+35	New	+$135K	﹤0.01%	2111

Other funds holding FBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cliff Asness's FBRX Position: Q3 2019 in Review

Cliff Asness sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 30 shares — an estimated $74K sold.

Cliff Asness first reported a position in FBRX in Q1 2019 and held it in 2 quarters. The position peaked at $143K in Q1 2019. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

Cliff Asness reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
Cliff Asness sold 30 Forte Biosciences shares in Q3 2019, an estimated $74K.
Cliff Asness first reported a position in Forte Biosciences in Q1 2019 and held it in 2 quarters.
Cliff Asness's Forte Biosciences position peaked at $143K in Q1 2019.
58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on AQR Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.